The biotechnology sector is facing headwinds entering 2022, after an explosive year for funding and initial public offerings.
Biotech companies rolled into 2021 with momentum stemming from innovation in the industry and its role in combating the Covid-19 pandemic. Stock prices surged early in the year and startups leapt onto the public markets.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
The investment world saw a great amount of deals within the biotech space.
Biotechnology company Senti Biosciences has agreed to go public through a merger with blank-check firm Dynamics Special Purpose Corp in a deal that values the combined company at $601 million.
Jeito Capital, a rapidly growing, new, independent Private Equity firm dedicated to biotech and biopharma, today announced the final closing of its first fund, Jeito I, at $630m, exceeding its original target of €500m. Jeito I is the largest European fund dedicated to supporting companies in the life sciences sector.
Ginkgo Bioworks reavealed plans to go public through a merger with a blank-check vehicle backed by former Hollywood executives Harry Sloan and Jeff Sagansky from Eagle Equity Partners, in one of the biggest such deals that values the biotech company at $17.5bn.
Source: Wall Street Journal
Can’t stop reading? Read more
Trump executive order paves way for private equity entry into $12tn retirement market
Trump executive order paves way for private equity entry into $12tn retirement market President...
Apollo acquires majority stake in Stream Data Centers to scale $38bn digital infrastructure push
Apollo acquires majority stake in Stream Data Centers to scale $38bn digital infrastructure push...
UK private equity adapts as carried interest landscape begins to shift
UK private equity adapts as carried interest landscape begins to shift The number of UK private...